Update on the Management of Inflammatory Breast Cancer

Abstract

Abstract Learning Objectives After completing this course, the reader will be able to: Recognize the differences in biology and clinical outcome of IBC compared with non-IBC. Summarize the standard of care for IBC. Identify molecular targets and novel agents for future treatments of IBC. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com Inflammatory breast cancer (IBC) is the most aggressive manifestation of primary breast carcinoma, with the clinical and biological characteristics of a rapidly proliferating disease. The multidisciplinary management of IBC has changed in the past 3 decades and is presently clearly outlined in sequence, with preoperative or neoadjuvant chemotherapy representing the mainstay of treatment. Anthracyclines and taxanes are the most effective cytotoxic agents in the management of primary breast cancer and should be the standard of treatment for women with IBC. Locoregional treatment includes radiotherapy with or without surgery and continues to play a major role after appropriate medical treatment. The many investigations into the particular molecular determinants of IBC development have provided several interesting new therapeutic targets. Combination regimens that include angiogenic modulators, farnesyl transferase inhibitors, and p53 modulators hold great promise in the medical management of IBC. Future therapeutic approaches should focus on these discoveries so that we can improve the overall prognosis for women with IBC.